Unexpected improvement in levodopa-induced dyskinesia and on-off phenomena after introduction of memantine for treatment of Parkinson's disease dementia

Journal of the American Geriatrics Society

Volumn 61, Issue 1, 2013, Pages 170-172

  Vidal, Edison I O ^a   Fukushima, Fernanda B ^a   Valle, Adriana P ^a   Villas Boas, Paulo J F ^a  

^a SÃO PAULO STATE UNIVERSITY UNESP   (Brazil)

Author keywords

[No Author keywords available]

Indexed keywords

DONEPEZIL; LEVODOPA; MEMANTINE;

ADULT; AGED; CASE REPORT; CLINICAL TRIAL (TOPIC); COGNITION; DRUG SAFETY; DYSKINESIA; HUMAN; LETTER; MALE; ON OFF PHENOMENON; PARKINSON DISEASE; TREATMENT RESPONSE; VISUAL HALLUCINATION;

AGED, 80 AND OVER; ANTIPARKINSON AGENTS; DEMENTIA; DOPAMINE AGENTS; DYSKINESIA, DRUG-INDUCED; HUMANS; LEVODOPA; MALE; MEMANTINE; MIDDLE AGED; PARKINSON DISEASE;

EID: 84872253989     PISSN: 00028614     EISSN: 15325415     Source Type: Journal    
DOI: 10.1111/jgs.12058     Document Type: Letter

References (10)

1. Hametner E, Seppi K, Poewe W,. The clinical spectrum of levodopa-induced motor complications. J Neurol 2010; 257: S268-S275.
2. Olanow CW, Stern MB, Sethi K,. The scientific and clinical basis for the treatment of Parkinson disease (2009). Neurology 2009; 72: S1-S136.
3. Lipton SA,. Paradigm shift in NMDA receptor antagonist drug development: Molecular mechanism of uncompetitive inhibition by memantine in the treatment of Alzheimer's disease and other neurologic disorders. J. Alzheimers Dis 2004; 6: S61-S74.
4. Aarsland D, Ballard C, Walker Z, et al. Memantine in patients with Parkinson's disease dementia or dementia with Lewy bodies: A double-blind, placebo-controlled, multicentre trial. Lancet Neurol 2009; 8: 613-618.
5. Leroi I, Overshott R, Byrne EJ, et al. Randomized controlled trial of memantine in dementia associated with Parkinson's disease. Mov Disord 2009; 24: 1217-1221.
6. Emre M, Tsolaki M, Bonuccelli U, et al. Memantine for patients with Parkinson's disease dementia or dementia with Lewy bodies: A randomised, double-blind, placebo-controlled trial. Lancet Neurol 2010; 9: 969-977.
7. Hanaǧasi HA, Kaptanoglu G, Sahin HA, et al. The use of NMDA antagonist memantine in drug-resistant dyskinesias resulting from L-dopa. Mov Disord 2000; 15: 1016-1017.
8. Varanese S, Howard J, Di Rocco A,. NMDA antagonist memantine improves levodopa-induced dyskinesias and "on-off" phenomena in Parkinson's disease. Mov Disord 2010; 25: 508-510.
9. Iravani MM, Jenner P,. Mechanisms underlying the onset and expression of levodopa-induced dyskinesia and their pharmacological manipulation. J Neural Transm 2011; 118: 1661-1690.
10. Chase TN, Konitsiotis S, Oh JD,. Striatal molecular mechanisms and motor dysfunction in Parkinson's disease. Adv Neurol 2001; 86: 355-360.